Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
New treatment option for ovarian cancer: PARP inhibitors
Meehan RS, Chen AP. "New treatment option for ovarian cancer: PARP inhibitors," Gynecologic Oncology Research and Practice, Vol. 3, 2016. (Free full text available)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Kim G, Ison 2, McKee AE, et al., "FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy," Clinical Cancer Research, Vol. 21, No. 19, October 2015. (Free full text available)
BRCA1 Functions as a Differential Modulator of Chemotherapy-induced Apoptosis
Jennifer E. Quinn, Richard D. Kennedy, Paul B. Mullan, Paula M. Gilmore, Michael Carty, Patrick G. Johnston and D. Paul Harkin. Cancer Research. Volume 63: p. 6221-6228, October 2003.
Improved survival in women with BRCA-associated ovarian carcinoma
Ilana Cass, M.D., Rae Lynn Baldwin, Ph.D., Taz Varkey, M.D., Roxana Moslehi, Ph.D., Steven A. Narod, M.D., Beth Y. Karlan, M.D. Cancer. Volume 97, Issue 9: p. 2187-2195, April 2003.
Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors
Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, U. Beller, G. Ben-Baruch, A. Fishman, H. Levavi, F. Lubin, J. Menczer, B. Piura, J.P. Struewing, B. Modan. Journal of Clinical Oncology. Volume 20, Issue 2: p. 463-466, January, 2002.
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma
Ofer Lavie, Gila Hornreich, Alon Ben-Arie, Gad Rennert, Yoram Cohen, Rehuven Keidar, Shlomi Sagi, Efrat Levy Lahad, Ron Auslander and Uzi Beller. Gynecologic Oncology, Volume 92, Number 2: p. 521-524, February 2004.